Spaymaco reports IPO planning progress
The article discusses Spimaco Saudi Pharmaceutical Company's plan to potentially offer a portion of its shares in Qassim Medical Services Company, of which it owns 57.23%. The company is considering a structure for the offering that includes either a direct sale or a capital increase involving new investors, with the aim of supporting company growth, enhancing governance and transparency, and expanding the investor base. The final percentage of shares to be offered will depend on the results of financial studies and the final valuation. Additionally, listing is expected to improve investment value, reduce debt, finance new pharmaceutical investments, or return a portion of proceeds to shareholders. This move is part of Spimaco's strategy to localize gene and cell therapies and strengthen the Kingdom’s capabilities in the biotechnology industry. The process may also contribute to advancing research and development, attracting patients from the region, and boosting medical tourism by building an integrated ecosystem that supports local manufacturing and content development.
Notice: This Is an AI-Generated Summary
Comments (0)